


PHARMACEUTICAL 2022



Corbus Pharmaceuticals Holdings Inc. Rank 263 of 466





PHARMACEUTICAL 2022



Corbus Pharmaceuticals Holdings Inc. Rank 263 of 466

The relative strengths and weaknesses of Corbus Pharmaceuticals Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Corbus Pharmaceuticals Holdings Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 32% points. The greatest weakness of Corbus Pharmaceuticals Holdings Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is 100%, being 22% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	100,205
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	17,008
Liabilities, Non-Current	21,615
Other Assets	5,133
Other Compr. Net Income	-62
Other Expenses	0
Other Liabilities	0
Other Net Income	10,349
Other Revenues	882
Property and Equipment	2,393
Research and Development	36,445
Selling, General and Administrative Expense	20,425

Output Variable	Value in 1000 USD
Assets	107,730
Liabilities	38,622
Expenses	56,871
Revenues	882
Stockholders Equity	69,108
Net Income	-45,640
Comprehensive Net Income	-45,672
Economic Capital Ratio	100%

